Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Factors impacting response to ICIs in mUC

Shilpa Gupta • 17 Feb 2021
GU Cancers 2021
Bladder Cancer Genitourinary Cancer Antibodies Atezolizumab Pembrolizumab

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC). The findings from this retrospective analysis, explained by Dr Gupta, showed no correlation between host and tumor factors, and treatment response or duration of response in patients. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Shilpa Gupta

1:11
The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer
Shilpa Gupta • 3 Jun 2023
1:02
The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape
Shilpa Gupta • 3 Jun 2023
6:02
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
Shilpa Gupta • 3 Jun 2023
2:06
MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer
Shilpa Gupta • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals